Showing results (1441-1450 of 3,637) with videos related to
Sort By:
Pageof 364
Breast (Edinburgh, Scotland)|August 27, 2013
Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategiesAnne Brecht Francken, Philip C Schouten, Eveline M A Bleiker, et al.Breast (Edinburgh, Scotland)|September 10, 2013
Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinicsL Varesco, V Viassolo, A Viel, et al.Breast (Edinburgh, Scotland)|October 1, 2013
Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapiesAna Catarina Pinto, Felipe Ades, Evandro de Azambuja, et al.Breast (Edinburgh, Scotland)|October 1, 2013
Extended adjuvant chemotherapy in endocrine non-responsive diseaseMarco Colleoni, Elisabetta MunzoneBreast (Edinburgh, Scotland)|October 1, 2013
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancerKathrin Strasser-Weippl, Tanja Badovinac-Crnjevic, Lei Fan, et al.Breast (Edinburgh, Scotland)|October 1, 2013
Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipientAron GoldhirschBreast (Edinburgh, Scotland)|October 1, 2013
Nutrition and physical activity influence on breast cancer incidence and outcomeRowan T ChlebowskiBreast (Edinburgh, Scotland)|October 1, 2013
The metastatic microenvironment of breast cancer: clinical implicationsR E Coleman, W Gregory, H Marshall, et al.Breast (Edinburgh, Scotland)|October 1, 2013
Extracellular matrix components in breast cancer progression and metastasisThordur OskarssonBreast (Edinburgh, Scotland)|October 1, 2013
Characterization and clinical impact of residual disease after neoadjuvant chemotherapyGiuseppe VialePageof 364